Organisation paid for research Program year 2024 Source: CMS Open Payments

Cincinnati Rheumatic Disease Study Group Inc

Neither a doctor nor a teaching hospital

Research payments

$591,418

170 payments

Through program year 2024, Cincinnati Rheumatic Disease Study Group Inc is reported as receiving $591,418 in research payments, across 170 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $2,636 2
2023 Research $23,116 8
2022 Research $76,964 38
2021 Research $221,946 60
2020 Research $144,176 28
2019 Research $122,580 34

Breakdown

Who paid Research payments · program years 2019–2024
  1. Eli Lilly and Company $365,944 68 payments
  2. AbbVie, Inc. $104,841 51 payments
  3. GlaxoSmithKline, LLC. $88,867 36 payments
  4. Sun Pharmaceutical Industries Inc. $20,759 8 payments
  5. Pfizer Inc. $9,044 4 payments
  6. Amgen Inc. $1,641 2 payments
  7. Genentech, Inc. $321 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Randomized, Active-Controlled, Parallel-Group, Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $141,179 7 payments
  2. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $126,844 9 payments
  3. A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $62,539 13 payments
  4. M13-542 $57,378 23 payments
  5. A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (Sle) $31,658 9 payments
  6. A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $27,054 2 payments
  7. A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $25,328 22 payments
  8. A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) $17,212 8 payments
  9. M13-549 $13,566 8 payments
  10. M13-538 $12,644 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record